HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors

HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors

Collaboration aims to evaluate HCB101 with InxMed’s investigational FAK inhibitor and FAP-targeted ADC to address stromal barriers, tumor fibrosis, immune exclusion, and myeloid-mediated immunosuppression

[Taipei, Shanghai, San Francisco | July 8, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).

Under the MOU, the two companies will leverage their respective investigational products and technology platforms to conduct preclinical and translational research exploring rational combination strategies for difficult-to-treat solid tumors.

The collaboration will focus on HCB101, HanchorBio’s clinical-stage SIRPα-Fc fusion protein targeting the CD47/SIRPα axis, in combination with InxMed’s investigational tumor microenvironment-modulating assets, including the small-molecule FAK inhibitor IN10018/ifebemtinib and the FAP-targeted ADC OMTX705. The companies aim to evaluate whether these complementary mechanisms may help address key therapeutic barriers in solid tumors, including stromal remodeling, extracellular matrix accumulation, tumor fibrosis, immune exclusion, and myeloid-mediated immune suppression.

The signing ceremony was attended by Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio, and Zaiqi Wang, M.D., Ph.D., Founder, Chairman, and CEO of InxMed, marking the beginning of a strategic research collaboration between two innovative biopharmaceutical companies focused on immuno-oncology, tumor microenvironment biology, and cancer drug resistance.

“We are pleased to establish this partnership with InxMed,” said Dr. Liu. “InxMed has built deep expertise in key pathways related to tumor microenvironment biology and cancer drug resistance, including FAK and integrin biology, which are highly complementary to HanchorBio’s immuno-oncology strategy. Through this collaboration, we aim to evaluate HCB101’s potential to block the CD47/SIRPα signaling axis and enhance macrophage-mediated recognition and phagocytosis of tumor cells, while combining it with IN10018/ifebemtinib and OMTX705 to address tumor fibrosis, stromal barriers, and immunosuppressive features of difficult-to-treat solid tumors from different mechanistic angles.”

Dr. Liu further noted that the collaboration may deepen the understanding of HCB101’s mechanism of action across diverse tumor microenvironments and provide a research foundation for potential expansion into stroma-rich, immune-excluded, or myeloid-enriched solid tumors, such as pancreatic cancer, cholangiocarcinoma, and diffuse-type gastric cancer.

“HCB101 has demonstrated encouraging potential as a macrophage-centered immunotherapy strategy across myeloid-enriched tumor settings,” said Dr. Wang. “InxMed is committed to overcoming cancer drug resistance, and our lead asset IN10018/ifebemtinib has entered late-stage clinical development, including a Phase III trial in China for platinum-resistant recurrent ovarian cancer, and has received Fast Track designation from the U.S. FDA. We believe this collaboration may create a complementary therapeutic strategy for highly fibrotic and treatment-resistant tumor microenvironments.”

Moving forward, the two companies will review preclinical and translational research findings to determine potential next steps. The collaboration is designed to generate mechanistic and translational insights into differentiated combination strategies that may address major therapeutic barriers in difficult-to-treat solid tumors.

About InxMed

Based in the United States and China, InxMed is a late clinical-stage biotechnology company focused on overcoming drug resistance in cancer therapy. Founded in 2017, the company targets tumor defense mechanisms through key signaling pathways, including focal adhesion kinase (FAK), integrin pathways, and cancer-associated fibroblasts (CAFs). Its lead program, IN10018/ifebemtinib, is in the registrational stage and has received Breakthrough Therapy Designation from China’s NMPA and Fast Track Designation from the U.S. FDA. InxMed is led by an experienced team committed to advancing innovative cancer therapies.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and address current limitations of existing immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.

Forward-Looking Statements

This press release contains forward-looking statements regarding HanchorBio’s research collaborations, clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.